Codexis Investor Conferences Participation
Codexis, Inc. (NASDAQ: CDXS), a prominent provider dedicated to enzymatic solutions that streamline and scale therapeutic manufacturing, is gearing up to engage with the investment community through a series of upcoming conferences. This move highlights the company’s commitment to transparently sharing its advancements and strategic vision in the healthcare sector.
Details of Upcoming Conferences
The Stifel Healthcare Conference
On November 18, management is set to participate in a notable fireside chat during The Stifel 2024 Healthcare Conference, where they will discuss the latest developments and innovations at Codexis.
The Jefferies London Healthcare Conference
Shortly after, on November 19, Codexis will be at The Jefferies London Healthcare Conference. This event provides another platform for management to share insights into the company’s unique enzymatic solutions and direction.
The 15th Annual Craig-Hallum Alpha Select Conference
Also on November 19, management will host one-on-one investor meetings at the Craig-Hallum Alpha Select Conference, allowing for in-depth discussions tailored to investor interests and inquiries.
The Stephens Annual Investment Conference
Finally, on November 21, Codexis will engage in another fireside chat at The Stephens Annual Investment Conference. Here, attendees can expect to learn more about the company’s ongoing projects and future plans.
Streaming and Replays
All fireside chats will be broadcast live, and interested parties can access the presentations through the Investor Relations section of Codexis’ website. Each session will also be archived for 90 days for those who cannot attend live.
About Codexis
Codexis stands at the forefront of enzymatic innovations, specializing in the development of efficient and scalable manufacturing solutions for therapeutics. The company utilizes its proprietary CodeEvolver technology platform to create and enhance high-performance enzymes and proteins tailored to solve complex challenges in pharmaceuticals and nucleic acid synthesis. Among its groundbreaking initiatives, Codexis is advancing its ECO Synthesis™ manufacturing platform aimed at revolutionizing RNAi therapeutic production through innovative enzymatic pathways. The enzymatic solutions provided by Codexis are designed to optimize production yields, reduce energy consumption, minimize waste, and enhance effectiveness in genomic and diagnostic applications.
Company Contacts
Investor Relations
Carrie McKim
(336) 608-9706
For inquiries: ir@codexis.com
Media Relations
Lauren Musto
(650) 421-8205
For press-related inquiries: media@codexis.com
Frequently Asked Questions
What is Codexis known for?
Codexis specializes in enzymatic solutions aimed at optimizing pharmaceutical manufacturing processes and improving the efficacy of therapeutics.
When are the upcoming conferences?
Codexis will participate in several conferences between November 18 and November 21.
How can I access the conference presentations?
Live webcasts of the presentations will be available on the Investor Relations section of the Codexis website, with recordings archived for 90 days.
What technology does Codexis use?
Codexis utilizes its proprietary CodeEvolver technology platform to develop high-performance enzymes for various applications.
Who can I contact for more information?
You can reach out to Carrie McKim or Lauren Musto for investor and media inquiries, respectively, via their provided contact details.